Cevostamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.

**Synonyms:** - Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A - Anti-FCRH5/CD3 BiTE Antibody BFCR4350A - Anti-FCRH5/CD3 TDB BFCR4350A - BFCR4350A - CEVOSTAMAB - FCRH5/CD3 T Cell Dependent Bispecific Antibody BFCR4350A - FCRH5/CD3 TDB Antibody BFCR4350A - RO7187797 - Recombinant Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A